STOCK TITAN

MeiraGTx Holdings plc Ordinary Shares - MGTX STOCK NEWS

Welcome to our dedicated page for MeiraGTx Holdings plc Ordinary Shares news (Ticker: MGTX), a resource for investors and traders seeking the latest updates and insights on MeiraGTx Holdings plc Ordinary Shares stock.

MeiraGTx Holdings plc (Nasdaq: MGTX) is a vertically integrated, clinical-stage gene therapy company with a focus on transforming the lives of patients through innovative genetic medicines. Based in London and New York, MeiraGTx pioneers gene therapies for a range of acquired and inherited disorders. The company's research spans serious neurodegenerative diseases such as Alzheimer's, Parkinson's, and ALS, as well as ocular diseases like inherited blindness and age-related macular degeneration. Additionally, MeiraGTx is developing treatments for xerostomia, a debilitating side effect of head and neck cancer radiation therapies.

MeiraGTx's product pipeline includes several advanced-stage clinical trials and preclinical research programs aimed at addressing significant unmet medical needs. Key pipeline products include AAV-CNGB3, AAV-CNGA3, and AAV-RPGR. These therapies target eye disorders, central nervous system conditions, and salivary gland dysfunctions.

The company has gained notable recognition and strategic investments from major pharmaceutical entities. Recently, Sanofi made a $30 million strategic investment in MeiraGTx, validating its Riboswitch gene regulation technology and xerostomia program. This investment underscores the broad potential of MeiraGTx's platform, which supports the development of breakthrough medicines for neurodegenerative and immune-mediated diseases.

MeiraGTx is also advancing its gene therapy manufacturing capabilities, with facilities in the United States, the United Kingdom, and the European Union. The company boasts state-of-the-art viral vector design and optimization, as well as a transformative gene regulation platform technology that allows precise, dose-responsive control of gene expression through oral small molecules.

Financially, MeiraGTx is well-positioned with a robust cash balance, strategic partnerships, and a strong pipeline of potential milestone payments. The company recently reported a $50 million milestone payment from Janssen Pharmaceuticals following the initiation of an extension study for the Phase 3 LUMEOS clinical trial for botaretigene sparoparvovec (bota-vec) for X-linked retinitis pigmentosa.

With a dedicated management team and a comprehensive end-to-end manufacturing infrastructure, MeiraGTx is poised to bring innovative genetic therapies to market, addressing both rare and prevalent diseases. For more information, visit www.meiragtx.com.

Rhea-AI Summary

MeiraGTx Holdings (Nasdaq: MGTX) will hold a webcast and conference call on December 17, 2020, at 8:00 a.m. ET to discuss the AAV-hAQP1 clinical program targeting radiation-induced xerostomia. They will share results from the first cohort of three patients in the Phase 1 AQUAx clinical trial, where one patient exhibited complete symptom resolution at the 12-month mark. The treatment showed good tolerance with no serious adverse effects. This update will feature insights from key presenters, including CEO Alexandria Forbes and trial investigator Dr. Michael Brennan.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
22.23%
Tags
conferences
-
Rhea-AI Summary

MeiraGTx Holdings plc (Nasdaq: MGTX) announced that CEO Alexandria Forbes, Ph.D., will present at the Evercore ISI 3rd Annual HealthCONx Conference on December 3, 2020, at 10:05 a.m. ET. The presentation will be available via a live webcast on the company's Investors page. MeiraGTx is a clinical-stage gene therapy company with six programs in development, focusing on inherited retinal diseases, neurodegenerative diseases, and severe forms of xerostomia. The company aims to address significant medical needs through innovative gene therapy solutions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.97%
Tags
conferences
-
Rhea-AI Summary

MeiraGTx Holdings plc (Nasdaq: MGTX) announced that Dr. Alexandria Forbes, CEO, will participate in a fireside chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference from December 1-3, 2020. The chat is pre-recorded and accessible on the Company's investor website, with a replay available for 90 days. MeiraGTx is a clinical stage gene therapy company focusing on inherited retinal diseases, neurodegenerative diseases, and xerostomia, with a strong pipeline and innovative gene regulation technology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.13%
Tags
conferences
Rhea-AI Summary

MeiraGTx Holdings plc (Nasdaq:MGTX) announced a public offering of 5,000,000 ordinary shares priced at $12.85 each, with expected gross proceeds of approximately $64.3 million. The underwriters also have a 30-day option to purchase an additional 750,000 shares. The offering is anticipated to close around November 23, 2020. The shares are offered under an effective registration statement previously filed with the SEC. The press release highlights potential risks and uncertainties related to the company's financial performance and market conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.03%
Tags
-
Rhea-AI Summary

MeiraGTx Holdings plc (NASDAQ:MGTX) announced a public offering of 5,000,000 ordinary shares, with a potential additional sale of 750,000 shares by underwriters. The offering is being managed by BofA Securities, Piper Sandler, Evercore ISI, Barclays, and Chardan. Proceeds will fund general corporate purposes, including working capital. This follows an effective shelf registration with the SEC from 2019. The final offering terms will be disclosed later. The company highlighted that the offering is subject to market conditions, and there are no guarantees of completion.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.03%
Tags
-
Rhea-AI Summary

MeiraGTx Holdings (Nasdaq: MGTX) recently presented encouraging data at the AAO 2020 Virtual Annual Meeting, revealing sustained improvements in retinal sensitivity for patients with X-linked retinitis pigmentosa (XLRP) after 12 months of treatment with AAV-RPGR, an investigational gene therapy. In the Phase 1/2 trial, six of seven patients showed stable or improved vision. The trial's primary focus is safety, with plans for a pivotal Phase 3 trial in collaboration with Janssen Pharmaceuticals.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.4%
Tags
none
Rhea-AI Summary

MeiraGTx Holdings, a clinical stage gene therapy company, announced that Alexandria Forbes, Ph.D., CEO, will present at the Barclays Gene Editing & Gene Therapy Summit on November 16, 2020, at 1:30 p.m. ET. The event can be accessed via a live webcast on the company's investors page. MeiraGTx has a robust pipeline with six clinical programs focusing on unmet medical needs in inherited retinal diseases, neurodegenerative diseases, and severe xerostomia. The company aims to advance innovative gene therapy treatments for these serious health conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.99%
Tags
conferences
-
Rhea-AI Summary

MeiraGTx (MGTX) announced robust financial results for Q3 2020, reporting a license revenue increase to $5.1 million from $3.6 million in Q3 2019. The firm is preparing to initiate a Phase 3 trial for AAV-RPGR, showing promising vision improvement from Phase 1/2 data. Despite a net loss of $6.4 million, down from $10.5 million a year prior, cash reserves stand at $179.3 million, sufficient to cover expenses into 2022. Construction of a new plasmid production facility in Ireland is on track for completion by year-end 2020, enhancing manufacturing capabilities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.79%
Tags
-
Rhea-AI Summary

MeiraGTx Holdings plc (Nasdaq: MGTX) announced the presentation of twelve-month results from its ongoing Phase 1/2 clinical trial of AAV-RPGR, an investigational gene therapy for X-linked retinitis pigmentosa (XLRP), at the American Academy of Ophthalmology 2020 Virtual Meeting from November 13-15, 2020. The data, which will be shared by presenter Michel Michaelides, has shown significant improvements in vision and retinal sensitivity. AAV-RPGR has received FDA Fast Track and Orphan Drug designations, enhancing its development prospects.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.64%
Tags
Rhea-AI Summary

MeiraGTx Holdings plc (MGTX) presented nine-month data from its Phase 1/2 clinical trial of AAV-RPGR, a gene therapy for X-linked retinitis pigmentosa, at the EURETINA 2020 Virtual Congress. The results showed significant improvements in retinal sensitivity and vision-guided mobility compared to untreated eyes. Specifically, six out of seven patients in low and intermediate dose cohorts maintained or improved retinal sensitivity. The therapy is well-tolerated, with plans to advance into a Phase 3 pivotal study following the ongoing success.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags

FAQ

What is the current stock price of MeiraGTx Holdings plc Ordinary Shares (MGTX)?

The current stock price of MeiraGTx Holdings plc Ordinary Shares (MGTX) is $6.64 as of December 2, 2024.

What is the market cap of MeiraGTx Holdings plc Ordinary Shares (MGTX)?

The market cap of MeiraGTx Holdings plc Ordinary Shares (MGTX) is approximately 518.9M.

What does MeiraGTx Holdings plc specialize in?

MeiraGTx specializes in developing gene therapies for acquired and inherited disorders, including neurodegenerative and ocular diseases.

Where is MeiraGTx Holdings plc based?

MeiraGTx is based in London, United Kingdom, and New York, United States.

What recent strategic investment did MeiraGTx receive?

MeiraGTx received a $30 million strategic investment from Sanofi.

What are some key products in MeiraGTx's pipeline?

Key products include AAV-CNGB3, AAV-CNGA3, and AAV-RPGR, targeting eye disorders and central nervous system conditions.

What was the recent milestone payment MeiraGTx received?

MeiraGTx received a $50 million milestone payment from Janssen Pharmaceuticals for the Phase 3 LUMEOS clinical trial.

What is MeiraGTx’s Riboswitch gene regulation technology?

It is a technology that allows precise, dose-responsive control of gene expression by oral small molecules, transforming the application of gene therapy.

What diseases is MeiraGTx targeting with its gene therapies?

MeiraGTx targets diseases such as Alzheimer's, Parkinson's, ALS, inherited blindness, age-related macular degeneration, and xerostomia.

What is the significance of the Sanofi investment in MeiraGTx?

Sanofi's investment validates MeiraGTx’s Riboswitch gene regulation technology and xerostomia program, highlighting the broad potential of their platform.

Does MeiraGTx have its own manufacturing facilities?

Yes, MeiraGTx has comprehensive gene therapy manufacturing capabilities in the US, UK, and EU.

Where can I find more information about MeiraGTx's clinical trials?

For more information, visit www.clinicaltrials.gov.

MeiraGTx Holdings plc Ordinary Shares

Nasdaq:MGTX

MGTX Rankings

MGTX Stock Data

518.94M
46.84M
24.25%
55.13%
2.15%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
NEW YORK